Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill

Advances in Therapy

Volumn 30, Issue 1, 2013, Pages 1-13

  Micks, Elizabeth A ^a   Jensen, Jeffrey T ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Contraception; Cycle control; Estradiol valerate and dienogest oral contraceptive pill; Heavy menstrual bleeding; Menstrual bleeding; Reproductive medicine

Indexed keywords

DIENOGEST PLUS ESTRADIOL VALERATE; ESTRADIOL; ESTRADIOL ENANTHATE; PLACEBO; DRUG DERIVATIVE; ESTRADIOL VALERATE, DIENOGEST DRUG COMBINATION; NANDROLONE; ORAL CONTRACEPTIVE AGENT; DRUG COMBINATION;

ACUTE HEART INFARCTION; CHRONIC TONSILLITIS; CONTRACEPTION; DRUG EFFICACY; DRUG INDICATION; HUMAN; KIDNEY COLIC; MENORRHAGIA; MENSTRUATION; OVARY CYST; OVULATION INHIBITION; REVIEW; SEXUALITY; SYSTEMATIC REVIEW; VULVA ABSCESS; VULVA DISEASE; DRUG COMBINATION; FEMALE; ANALOGS AND DERIVATIVES;

CONTRACEPTIVES, ORAL; DRUG COMBINATIONS; ESTRADIOL; FEMALE; HUMANS; MENORRHAGIA; NANDROLONE;

EID: 84891504442     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0071-3     Document Type: Review

References (64)

1. Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am. 2000;27:705-21.
2. Hatcher RA, Trussell J, Nelson A, et al. Contraceptive technology. 20th edition. New York, NY: Ardent Media; 2011.
3. Prentice A. Fortnightly review. Medical management of menorrhagia. BMJ. 1999;319:1343-5.
4. National Collaborating Centre for Women's and Children's Health. Heavy menstrual bleeding. Commissioned by the National Institute for Health and Clinical Excellence. NHS NICE website. Available at: http://www.nice.org.uk/ nicemedia/pdf/ CG44FullGuideline.pdf. Accessed May 12 2011.
5. Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol. 2000;96:913-20.
6. Farquhar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev. 2009:CD000154.
7. Nilsson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol. 1971;110:713-20.
8. Mishell DR, Jr. Noncontraceptive health benefits of oral steroidal contraceptives. Am J Obstet Gynecol.1982;142:809-16.
9. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N ZJ Obstet Gynaecol. 1991;31:66-70.
10. FDA approved drug products. U.S. Food and Drug Administration wesbite. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. cfm. Accessed Aug 30 2012.
11. Meade TW. Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol. 1988;158:1646-52.
12. Goebelsmann U, Mashchak CA, Mishell DR, Jr. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol. 1985;151:868-77.
13. Krishnan S, Kiley J. The lowest-dose, extendedcycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 μg/ levonorgestrel 100 μg + ethinyl estradiol 10 μg. Int J Womens Health. 2010;2:235-9.
14. Gallo MF, Nanda K, Grimes DA, Schulz KF. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2005:CD003989.
15. Lindberg UB, Crona N, Stigendal L, Teger-Nilsson AC, Silfverstolpe G. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemost. 1989;61:65-9.
16. Wiegratz I, Lee JH, Kutschera E, Winkler UH, Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004;70:97-106.
17. Hoffmann H, Moore C, Zimmermann H, et al. Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives. Exp Toxicol Pathol. 1998;50:458-64.
18. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol. Fertil Steril. 1993;60:616-9.
19. Schubert W, Cullberg G. Ovulation inhibition with 17 beta-estradiol cyclo-octyl acetateand desogestrel. Acta Obstet Gynecol Scand. 1987;66:543-7.
20. Astedt B, Jeppsson S, Liedholm P, Rannevik G, Svanberg L. Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17 beta-oestradiol. Br J Obstet Gynaecol. 1979;86:732-6.
21. Hirvonen E, Allonen H, Anttila M, et al. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas. 1995;21:27-32.
22. Csemiczky G, Dieben T, Coeling Bennink HJ, Landgren BM. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg esogestrel for 21 days, followed by 0.030 mg esogestrel only for 7 days. Contraception. 1996;54:333-8.
23. Oettel M, Breitbarth H, Elger W, et al. The harmacological profile of dienogest. Eur J ontracept Reprod Health Care. 1999;4:2-13.
24. Mosher WD, Martinez GM, Chandra A, Abma JC, illson SJ. Use of contraception and use of family lanning services in the United States: 1982-2002. dv Data. 2004:1-36.
25. Chandra A, Martinez GM, Mosher WD, Abma C, Jones J. Fertility, family planning, and reproductive health of U.S. women: data from he 2002 National Survey of Family Growth. Vital Health Stat 23. 2005:1-160.
26. Singh S, Sedgh G, Hussain R. Unintended regnancy: worldwide levels, trends, and utcomes. Stud Fam Plann. 2010;41:241-50.
27. Speroff L, Darney PD. A clinical guide for ontraception. 5th edition. Philadelphia: Wolters luwer Health/Lippincott Williams & Wilkins;2011.
28. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of ong-acting reversible contraception. N Engl J Med.2012;366:1998-2007.
29. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. enstrual blood loss and iron deficiency. Acta Med sand. 1966;180:639-50.
30. Zakherah MS, Sayed GH, El-Nashar SA, haaban MM. Pictorial blood loss assessment hart in the evaluation of heavy menstrualbleeding: diagnostic accuracy compared to lkaline hematin. Gynecol Obstet Invest.2011;71:281-4.
31. Endrikat J, Shapiro H, Lukkari-Lax E, Kunz , Schmidt W, Fortier M. A Canadian, multicentre study comparing the efficacy of levonorgestrel-releasing intrauterine system to an oral contraceptive in women with diopathic menorrhagia. J Obstet Gynaecol Can.2009;31:340-7.
32. Shaaban MM, Zakherah MS, El-Nashar SA, ayed GH. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception. 2011;83:48-54.
33. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999;181:1263-9.
34. Speroff L, Fritz M. Clinical Gynecologic Endocrinology and Infertility. 7th edition. Baltimore: Lippincott Williams & Wilkins; 2004.
35. Bitzer J, Parke S, Roemer T, Serrani M. Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest. Int J Womens Health. 2011;3:127-32.
36. Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, openlabel studies. Contraception. 2008;78:218-25.
37. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142-9.
38. Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception. 2003;67:9-13.
39. Sulak P, Scow R, Preece C, Riggs M, Kuehl T. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261-6.
40. Mabey R, Parke S, Mellinger U, Serrani M, Jensen J. Hormone withdrawal-associated symptoms: comparison of estradiol valerate/dienogest versus ethinylestradiol/norgestimate. Poster presentation at: American College of Obstetricians and Gynecologists Annual Clinical Meeting; May 5-9, 2012; San Diego, CA. Available at: http://www.postersessiononline.com/173580348- eu/congresos/60acog/aula/-Mo-8-60acog.pdf. Accessed Oct 17 2012.
41. Macias G, Merki-Feld G, Parke S, Mellinger U, Serrani M. Hormone withdrawal-associated symptoms in women taking combined oral contraceptives: comparison of estradiol valerate/ dienogest versus ethinylestradiol/ levonorgestrel. Poster presentation at: International Society of Gynecological Endocrinology Meeting; March 7-10, 2012; Firenze, Italy. Available at: http:// www.isge2012.com/abstracts-posters/. Accessed Oct 17 2012.
42. Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol. 2011;117:33-40.
43. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception. 2006;74:100-3.
44. Have you missed your Natazia pill? Natazia® website. Available at: http://www.natazia.com/ missed-your-pill.html. Accessed Aug 30 2012.
45. Palacios S, Wildt L, Parke S, Machlitt A, Romer T, Bitzer J. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol. 2010;149:57-62.
46. Nelson A, Sampson-Landers C, Parke S, Jensen J. Efficacy of estradiol valerate/dienogest OC: results of 3 large studies in North America and Europe. Abstract plus poster presentation at: 57th Annual Clinical Meeting of the American College of Obstetricians & Gynecologists; May 2-6 2009, Chicago, IL.
47. Natazia® Prescribing Information. Bayer Healthcare website. Available at: http://berlex. bayerhealthcare.com/html/products/pi/natazia- pi.pdf. Accessed Aug 30 2012.
48. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception. 2007;75:16-22.
49. Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80:436-44.
50. Jensen J, Machlitt A, Mellinger U, Schaefers M, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol. 2011;117:777-87.
51. Fraser IS, Romer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reproduct. 2011;26:2698-708.
52. Wasiak R, Filonenko A, Vanness DJ, et al. Impact of estradiol-valerate/ dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding. Int J Womens Health. 2012;4:271-8.
53. Fraser IS, Jensen J, Schaefers M, Mellinger U, Parke S, Serrani M. Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest. Contraception. 2012;86:96-101.
54. Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D. 2011;11:159-70.
55. Junge W, Mellinger U, Parke S, Serrani M. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011;31:573-84.
56. Caruso S, Agnello C, Romano M, et al. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J Sex Med. 2011;8:2841-50.
57. Nappi R, Davis S, Bitzer J, et al. Exploring the effect of oral contraceptives on female sexual function. Poster presentation at: Endocrine Society Meeting; June 23-26, 2012; Houston, TX. Available at: http://edrv.endojournals.org/ cgi/content/meeting-abstract/32/03-Meeting Abstracts/P1-315?sid=5fbd5310-81c6-4888-8c6ba5c64c36ae42. Accessed Oct 17 2012.
58. Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception. 1995;51:341-6.
59. Strufaldi R, Pompei LM, Steiner ML, et al. Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels. Contraception. 2010;82:147-54.
60. International Active Surveillance Study - Safety of Contraceptives: Role of Estrogen (INAS-SCORE). Clinical Trials website. Available at: http://clinicaltrials.gov/ct2/show/ NCT01009684?term=inas&rank=1. Accessed Jun 21 2011.
61. Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid- related menorrhagia. Int J Gynaecol Obstet. 2011;112:126-30.
62. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116:865-75.
63. Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116:625-32.
64. Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG. 2005;112:1121-5.